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Abstract
Antimicrobial peptides (AMPs) have been proposed as new class of antimicrobial
drugs, following the increasing prevalence of bacteria resistant to antibiotics. Syn-
thetic AMPs are functional analogues of highly evolutionarily conserved immune
effectors in animals and plants, produced in response to microbial infection.
Therefore, the proposed therapeutic use of AMPs bears the risk of ‘arming the
enemy’: bacteria that evolve resistance to AMPs may be cross-resistant to
immune effectors (AMPs) in their hosts. We used a panel of populations of
Staphylococcus aureus that were experimentally selected for resistance to a suite of
individual AMPs and antibiotics to investigate the ‘arming the enemy’ hypothe-
sis. We tested whether the selected strains showed higher survival in an insect
model (Tenebrio molitor) and cross-resistance against other antimicrobials in
vitro. A population selected for resistance to the antimicrobial peptide iseganan
showed increased in vivo survival, but was not more virulent. We suggest that
increased survival of AMP-resistant bacteria almost certainly poses problems to
immune-compromised hosts.
Introduction
Antimicrobial peptides (AMPs) are major components of
immune defences in multicellular organisms (Tzou et al.
2002; Koprivnjak and Peschel 2011). Bacterial resistance to
AMPs is rarely observed in environmental or clinical iso-
lates, leading some to suggest that these molecules are
‘resistance proof’ (Zasloff 2002). Based on these observa-
tions and the decline in effectiveness of antibiotics, AMPs
have been proposed as the basis of synthetic drugs that
could be used to fight human infection (Zasloff 2002; Red-
dy et al. 2004; Giuliani et al. 2007).
In vitro experiments have now demonstrated that, con-
trary to earlier expectations, AMPs are not resistance proof.
Resistance evolved at low cost within just a few hundred
generations in Escherichia coli, Pseudomonas fuorescens
(Perron et al. 2006), Salmonella enterica (Pr€anting et al.
2008), Streptococcus pneumoniae (Habets et al. 2012) and
Staphylococcus aureus (Dobson et al. 2013). Recent work
has shown that pexiganan-resistant S. aureus can also be
cross-resistant to human neutrophil defensin-1, a human
AMP (Habets and Brockhurst 2012).
Importantly, the repertoire of AMP resistance mecha-
nisms is limited (reviewed in Peschel and Sahl 2006;
Koprivnjak and Peschel 2011; Gruenheid and Le Moual
2012). The fact that some microbes can utilise these few
resistance mechanisms to inhabit AMP-rich environments,
for example Pseudomonas aeruginosa in mucosal tissue
(Gruenheid and Le Moual 2012), suggests that such mecha-
nisms could be effective in conferring resistance to a broad
range of AMPs. Thus, should therapeutic use of AMPs
becomes a reality, providing selective conditions for the rise
and spread of bacteria resistant to a broad spectrum of
AMPs (cross-resistance), we risk ‘arming the enemy’ by
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equipping pathogens with tools for increased resistance to
the immune system (Bell and Gouyon 2003; Buckling and
Brockhurst 2005). To date, there has been no thorough test
of the survival and virulence of a range of AMP-resistant
bacteria in an animal host.
We recently demonstrated that fitness costs of AMP
resistance are unlikely to constrain evolution in the gram-
positive bacterium S. aureus. However, simultaneous selec-
tion at the same intensity by a combination of two AMPs
constrained resistance (Dobson et al. 2013). The experi-
mentally evolved strains from this study provide a resource
with which we can comparatively explore the potential lim-
its of shifts in survival of both bacteria and host after infec-
tion. AMPs play a critical role in insect innate immune
defences (Moon et al. 1994; Lemaitre and Hoffmann 2007;
Chae et al. 2012), which are therefore well suited to investi-
gate the potential problems of AMP cross-resistance. As a
model host, we use the mealworm Tenebrio molitor. This
beetle exhibits a long-lasting humoral antimicrobial
immune response to persistent S. aureus infection (Haine
et al. 2008a), which is largely dependent on induction of
AMPs (Johnston et al. 2014). We therefore predicted that
infection titters in this system are sensitive to variation in
AMP resistance. We used this host to parameterize survival
of AMP-resistant bacteria in vivo, which we complemented
with in vitro assays of cross-resistance. We also assessed the
effects of these populations on survival of infected hosts.
This allowed us to address the potential risk of AMP ther-
apy for the first time in an animal host.
Materials & methods
Bacteria and stressor selection
We designed a proof-of-principle study to test the effects of
AMP resistance on host and pathogen. All bacterial strains
were S. aureus that we had previously selected for resis-
tance against antibiotics or antimicrobial peptides (Dobson
et al. 2013; Table 1). Briefly, these cultures were grown
from an isogenic ancestor in the absence of selection for
10 days by serial passage. They were then inoculated into
media containing one of the AMPs pexiganan, iseganan or
melittin. Procedural controls were the antibiotics vancomy-
cin or streptomycin. Untreated controls were inoculated
into unsupplemented media. All AMPs/antibiotics were
suspended at a concentration sufficient to inhibit 50%
growth of the ancestral bacteria. Five replicate populations
were established per AMP/antibiotic, and cultures were
grown by daily serial passage. Concentration of each
respective AMP/antibiotic was doubled weekly. Popula-
tions were grown for up to 4 weeks, or until extinction
shortly after the beginning of week 3 (vancomycin treat-
ment only). The ancestral population was constitutively
tetracycline resistant, allowing us to selectively recover
them from T. molitor postinfection on media containing
tetracycline. These populations demonstrated equivalent
performance in fitness assays.
Bacteria preparation for infection and cross-resistance
studies
Before infecting T. molitor, we pooled evolved populations
from within treatments in equal proportion, for two rea-
sons. First, ‘public goods’, in which one or a few clones in a
bacterial population evolve traits that benefit the whole
population, are known to mediate antibiotic resistance (Lee
et al. 2010). AMPs can be inactivated by extracellular pep-
tidases (Peschel and Sahl 2006; Koprivnjak and Peschel
2011), so population-level resistance, mediated, for exam-
ple, by ‘public goods’, seems particularly likely for AMP-
resistant bacteria. Second, real infections are commonly
caused by mixed populations, not isogenic strains, and this
has also been shown in S. aureus (Balmer and Tanner
2011). We therefore sought to assay the population-level
processes relevant to a real infection, which can establish
the limits of phenotypic space of AMP-resistant bacteria
equally well as equivalent experiments with isolated clones.
Populations were pooled by partially thawing glycerol
stocks until 100 lL could be removed, which was inocu-
Table 1. Bacterial populations pooled for Tenebrio molitor infection.
Culture (treatment/timepoint) Description [see Dobson et al. (2013) for protocol]
Ancestor Preselection control. All other cultures were derived from this population
Iseganan, day 28 AMP-selected population. Selected by iseganan in vitro for 28 days. Highly resistant by in vitro assay.
Melittin, day 28 AMP-selected population. Selected by melittin in vitro for 28 days. Constituent populations showed variable
resistance by in vitro assay.
Pexiganan, day 28 AMP-selected population. Selected by pexiganan in vitro for 28 days. Grew at low density for latter 14 days of
selection. Re-assaying (this paper) demonstrates moderately increased resistance.
Unselected, day 28 Unselected day 28 control for drift in the absence of selection. Serially passaged in growth medium without
stressors for 28 days.
Streptomycin, day 28 Antibiotic-selected control. Selected by streptomycin in vitro for 28 days.
Vancomycin, day 14 Antibiotic-selected control. Selected in vitro by vancomycin for 14 days. Showed apparent increase in resistance
then rapid extinction on days 17–18.
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lated into 5 mL LB and grown to stationary phase. 500 lL
aliquots of these cultures were spun for 5 min at 4500 g.
Pellets from each treatment were then pooled by commu-
nal resuspension in 1 mL tryptic soy broth (Sigma-Aldrich
T8907, Munich, Germany) with glycerol (80% water: 20%
glycerol v/v) and frozen at 90°C.
Cultures of these pooled bacteria were prepared by
directly inoculating 5 mL LB with a scrape of the pooled
stock and grown for 24 h at 30°C with shaking. Twenty-
four hour, cultures were pelleted by centrifugation at
4500 g for 5 min, then washed and resuspended in an
equal volume of sterile PBS (NaCl 150 mM, Na2HPO4
10 mM, pH 6.5).
To check for contamination and to quantify CFU in the
inocula, 50 lL of each inoculated culture (diluted 9 105)
was plated with 20 sterile glass beads on LB (Sigma-Aldrich
L2897) 1.5% agar containing tetracycline and amphoteri-
cin-B as previously. Plates were incubated for 24 h at 37°C
and photographed. CFUs were automatically counted using
OpenCFU (Geissmann 2013).
Tenebrio molitor culture and infection
Tenebrio molitor were purchased as final-instar larvae from
a commercial supplier (www.livefoods.co.uk) and grown in
rat chow (Harlan Laboratories, Shardlow, UK) in an insec-
tary at 26°C  1 in a 12:12-h light/dark cycle. F1 offspring
of these beetles were used for infection experiments.
Females were sexed as pupae and kept individually in rat
chow, eclosion was recorded daily, and all beetles were vir-
gins between 7 and 10 days old when used.
Pathogenicity and bacterial survival were assessed in
T. molitor by injection with our experimentally evolved
S. aureus. Beetles were surface-sterilized by swabbing the
ventral abdomen with 80% EtOH, and loading a fine-
pulled glass electrode (Narishige) with ~105 CFU inoculum
suspended in 5 lL PBS. Inocula were injected between the
third and forth abdominal sternites into the haemocoel.
Negative controls were injected with 5 lL sterile PBS.
Quantifying infection
Staphylococcus aureus were recovered from T. molitor 24 h
after infection, coincident with peak AMP expression
(Johnston et al. 2014). Controls were injected with sterile
PBS to identify any tetracycline-resistant contaminants.
Bacteria were recovered using a ‘perfusion bleed’ assay,
refined from that of (Haine et al. 2008b). The beetle cuticle
was surface-rinsed for ~45–60 s in 80% EtOH, to remove
cuticular contaminants. Genitalia were everted by gently
squeezing the abdomen and swabbed with 80% EtOH, and
a small incision was made with a scalpel. A 30-gauge needle
was inserted through the plural membrane exposed
between the abdomen and thorax on the side of the body
laterally opposite to the genital incision and pushed into
the abdominal haemocoel. 500 lL sterile PBS was pushed
through the needle, washing haemolymph out of the abdo-
men and into a sterile collection tube via the genital inci-
sion. 50 lL of perfused haemolymph samples was plated
with 20 sterile glass beads on LB 1.5% agar plates contain-
ing tetracycline and amphotericin-B to select the experi-
mental strains from the background insect flora. Plates
were incubated and colonies counted as previously. CFU
counts were then extrapolated to estimates per beetle. If
bacteria grew at uncountably high densities, the sample was
censored and assigned the maximum number of CFUs that
could be counted by our assay (13 000).
Pathogenesis assays
Beetles were injected 8 days after eclosion (50 individuals
per treatment) as in the bacterial survival assay, and mor-
tality of each individual was checked at least every 2 days.
Mortality was recorded when beetles ceased to respond to
mechanical stimulation.
Cross-resistance assays
Cultures for in vitro cross-resistance assays were grown
from pooled stocks in M€uller-Hinton broth (Sigma-Aldrich
70192, 5 lg mL1 tetracycline, 5.6 lg mL1 amphoteri-
cin-B) for 18 h at 30°C with shaking, to a density of
5 9 106 CFU mL1. We tested resistance of our evolved
populations to the antimicrobial peptides pexiganan (cour-
tesy of Michael Zasloff, Georgetown University, USA),
melittin (Sigma-Aldrich M2272) and a 50:50 combination
of the two (PGML). Unfortunately, we were unable to
obtain sufficient iseganan for a fully reciprocal design.
Resistance of naive bacteria to these antimicrobials (cross-
resistance) was determined by dose-response assays in
100 lL volumes per well in sterile 96-well microtitre plates,
using a twofold dilution series from 64 to 0.125 lg mL1
and an additional well of unsupplemented M€uller-Hinton
broth. 10 lL of culture was added to each well and OD595
was measured every hour for 6 h, allowing for exponential
growth. MIC was determined as the first concentration in
which no growth was detected after 6 h.
Data analysis
PBS-injected controls revealed no contamination and so
were excluded from further analyses. We performed two
analyses of CFU counts. All data were analysed in R version
3.0.2 (R Core Team 2013). To account for censored data
from overgrown plates, we used the MCMCglmm package
(Hadfield 2010). This innovative package uses Markov
© 2014 The Authors. Evolutionary Applications published by John Wiley & Sons Ltd 7 (2014) 905–912 907
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chain Monte Carlo techniques to fit generalized linear
models in a Bayesian framework, with a wide range of
potential error distributions. These distributions include
the censored Poisson distribution, which we used to
account for censored data from our CFU counts. This
model was fitted with 1.3 million iterations, thinning inter-
val of 1000 and a burn-in of 300 000 generating posterior
coefficients for each treatment group with 95% confidence
intervals. To verify these results, we additionally fitted a
standard frequentist GLM with a quasi-Poisson distribu-
tion after excluding the censored samples, using the R base
GLM function. Post hoc multiple comparisons of frequen-
tist GLM were performed using the general linear hypothe-
sis testing (glht) function from the R multcomp package.
The two approaches yielded congruent results, so we pres-
ent results from the more powerful MCMCglmm.
Survival of beetles in pathogenesis assays was censored
21 days after eclosion. The data were analysed with an
accelerated failure time (AFT) survival model with a Wei-
bull distribution, using the survival package (Therneau
2013).
Results
Selected Staphylococcus aureus resistance in Tenebrio
molitor
There was significant treatment-specific variation in
survival of selected S. aureus populations 24 h after inocu-
lation into T. molitor (Fig. 1A and B, Table 2). Of the
AMP-selected lines, iseganan-selected bacteria showed
higher survival in the host than the ancestor
(pMCMC = 0.002), and pexiganan-selected bacteria showed
a trend towards higher survival (pMCMC = 0.052). Melittin-
selected bacteria did not survive significantly better than
the ancestral population, but there was significantly more
variance in this group than in the rest of the data set
together (F-test, F = 2.48, df = 8, 64, P < 0.05), suggesting
a more diverse mix of resistant and nonresistant clones in
this inoculum than in those in other treatments. Relative to
the ancestral population, vancomycin-selected and unse-
lected lines showed no differences (pMCMC > 0.1). Strepto-
mycin-selected bacteria showed increased survival
compared with the ancestral strain as well as the unselected
control strain (pMCMC = 0.02). Results from a frequentist
GLM, along with Tukey’s multiple comparisons, are pre-
sented in Table S1.1 and S1.2.
Pathogenicity of selected Staphylococcus aureus to
Tenebrio molitor
Bacterial selection line had significant effects on the patho-
genicity of some strains (Fig. 2). Our iseganan-selected
bacteria became less pathogenic streptomycin- and pexiga-
nan-selected and unselected controls (Table 3). Compari-
sons between beetles injected with PBS to beetles infected
with bacteria revealed the same pattern of differences as
(A)
(B)
Ancestor Iseganan Melittin Pexiganan Passaged Streptomycin Vancomycin
Figure 1 24-h Staphylococcus aureus persistence in Tenebrio molitor.
AMP- and antibiotic-selected S. aureus populations were inoculated
into T. molitor, and recoverable cells quantified after 24-h exposure. (A)
The box and whisker plots present the density of each bacterial popula-
tion in T. molitor as the average log10 CFU per beetle, showing medi-
ans, first and third quartiles and 5th and 95th percentiles. (B) MCMC
techniques were used to fit a generalized linear model to the CFU data,
because certain plates were uncountable and were therefore right-cen-
sored. The MCMCglmm used a censored Poisson distribution to esti-
mate differences between treatments. Solid line at 0 represents the
intercept (ancestral population), 95% confidence intervals repre-
sented by dashed lines. The points represent coefficients of each treat-
ment 95% confidence intervals. Iseganan (pMCMC = 0.002),
streptomycin (pMCMC = 0.02) and pexiganan (pMCMC = 0.052) showed
significantly more immunoresistance than the ancestor strain. Frequen-
tist GLM and multiple comparisons are presented in supplementary
material.
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seen in the iseganan group, indicating that treatment by is-
eganan reduced pathogenicity of the population. Pexiga-
nan-selected and unselected bacteria were also more
pathogenic than the vancomycin-selected population.
Assessment of cross-resistance in vitro
We did not find strong evidence of S. aureus cross-resis-
tance to AMPs through in vitro assays (Fig. 3). Relative to
Table 2. Analysis of persistence of selected bacteria (CFU counts) in
vivo by MCMCglmm with censored Poisson distribution.
Treatment level
Posterior
mean
(coefficient)
95%
confidence
interval
+95%
confidence
interval pMCMC
Intercept (Ancestor) 5.98 5.29 6.72 <0.001
Iseganan +2.81 +1.57 +4.16 0.002
Melittin +0.28 0.91 +1.55 0.632
Pexiganan +1.12 0.02 +2.40 0.052
Unselected 0.12 1.42 +1.06 0.832
Streptomycin +1.49 +0.05 +2.61 0.020
Vancomycin 0.94 2.15 +0.31 0.134
Table 3. Comparisons of survival Tenebrio molitor (parametric survival model with Weibull distribution) infected with AMP or antibiotic-selected
Staphylococcus aureus. Significant effects are emboldened.
Treatment A Treatment B Estimate SE Z Adjusted P
Iseganan Ancestor 0.2812 0.10148 2.771 0.10201
Melittin Ancestor 0.12926 0.09758 1.325 0.8892
PBS Ancestor 0.23816 0.09949 2.394 0.24299
Pexiganan Ancestor 0.14656 0.09035 1.622 0.73596
Unselected Ancestor 0.19249 0.09083 2.119 0.40125
Streptomycin Ancestor 0.10046 0.0953 1.054 0.96572
Vancomycin Ancestor 0.15832 0.09844 1.608 0.74472
Melittin Iseganan 0.15194 0.10483 1.449 0.83313
PBS Iseganan 0.04305 0.1062 0.405 0.99992
Pexiganan Iseganan 0.42776 0.09885 4.327 <0.001
Unselected Iseganan 0.47369 0.09939 4.766 <0.001
Streptomycin Iseganan 0.38166 0.10313 3.701 0.00537
Vancomycin Iseganan 0.12288 0.1055 1.165 0.9415
PBS Melittin 0.10889 0.10299 1.057 0.96512
Pexiganan Melittin 0.27582 0.09473 2.912 0.07005
Unselected Melittin 0.32175 0.09523 3.379 0.01647
Streptomycin Melittin 0.22972 0.09934 2.312 0.28519
Vancomycin Melittin 0.02906 0.10211 0.285 0.99999
Pexiganan PBS 0.38471 0.09677 3.975 0.00164
Unselected PBS 0.43064 0.0973 4.426 <0.001
Streptomycin PBS 0.33861 0.10119 3.346 0.01842
Vancomycin PBS 0.07984 0.1037 0.77 0.99456
Unselected Pexiganan 0.04593 0.08761 0.524 0.99954
Streptomycin Pexiganan 0.0461 0.0923 0.499 0.99966
Vancomycin Pexiganan 0.30488 0.09564 3.188 0.03111
Streptomycin Unselected 0.09203 0.09279 0.992 0.97557
Vancomycin Unselected 0.35081 0.09615 3.648 0.00647
Vancomycin Streptomycin 0.25878 0.10018 2.583 0.16099
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Figure 2 Postinfection survival of Tenebrio molitor infected with
selected and unselected Staphylococcus aureus. The proportion of
T. molitor survival after infection with each bacterial population and
PBS control is presented over 21 days. Summary statistics are presented
in Table 3.
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the ancestor, melittin- and pexiganan-selected bacteria
showed increased resistance to the compounds that they
had been selected by. Melittin-selected bacteria additionally
showed increased resistance to PGML. Iseganan-selected
bacteria showed decreased resistance to melittin, pexiganan
and PGML, suggesting a cost of iseganan resistance in this
context. All other bacteria showed equal pexiganan, melit-
tin and PGML susceptibility as the ancestor.
Discussion
Our studies show increased survival of iseganan-resistant
S. aureus in vivo, consistent with the hypothesis of AMP
therapy having the potential to ‘arm the enemy’. This result
associates evolved resistance to a single AMP, as would be
the case in a topical application, with enhanced survival in
the face of an AMP-dependent immune response. Our
streptomycin-selected procedural control showed some-
what increased survival in the beetle. As streptomycin
interferes with bacterial ribosomes – which to our knowl-
edge are not affected by insect immune systems – without
further functional studies, this result can only be attributed
to increased ‘vigour’ after selection (Kawecki et al. 2012).
Nevertheless, the iseganan-selected bacteria survived in
the host on average 3.7 times better (adjusted P < 0.005)
than the streptomycin-selected bacteria (Fig. 1, Table
S1.2.), which can be most parsimoniously attributed to
differences arising from selection for iseganan resistance.
Further work is required to attribute these effects to spe-
cific mechanisms.
We observed some congruence between in vivo sur-
vival of bacteria in this study and in vitro resistance in
our previous (Dobson et al. 2013), but this pattern
must be interpreted with caution. Iseganan-selected bac-
teria were highly iseganan-resistant in vitro and also sur-
vived well in T. molitor. Melittin-selected bacteria
showed striking interpopulation variability in resistance
in vitro, and considerable variation in the numbers of
bacteria recovered from beetles. However, our pexiga-
nan-resistant bacteria, which performed poorly under
selection in vitro, survived somewhat better in vivo.
Additionally, the observed increase in survival in the
host could not be clearly predicted from the in vitro
cross-resistance data presented here. This highlights that
in vivo testing is crucial to explore the potential of
cross-resistance in a natural context (Martinez 2008). It
would be of value in future to assess how many muta-
tions arose in iseganan-selected strains, and whether
genetic variants associated with improved survival in the
host are also associated with iseganan resistance. As
there are no data on the number of generations that
each strain grew for under selection, we cannot estimate
the number of mutations that arose in each of our
populations, and whether these were equivalent across
treatments. However, these strains were all able to grow
to roughly equivalent density (optical density, 595 nm)
in their respective growth media, and there were no dif-
ferences between the fitness index (calculated from
growth rate) of populations selected for resistance to is-
eganan or streptomycin (Dobson et al. 2013), indicating
that effects in the iseganan-selected bacteria are not
likely due to accrual of more mutations than other
populations.
Increased in vivo survival of AMP-selected bacteria raises
concerns about the eligibility of AMPs as therapeutic anti-
microbial or immunomodulatory drugs (Hancock 2000;
Zasloff 2002; Easton et al. 2009; Yeung et al. 2011). Our in
vivo data augment the proposition that clinical use of
AMPs could select widespread resistance to the immune
system. Habets and Brockhurst (2012) demonstrated in
vitro cross-resistance to humanneutrophil defensin-1 in
pexiganan-resistant S. aureus, although this effect was not
universal amongst resistant clones. However, Pr€anting
et al. (2008) were unable to identify cross-resistance to a
panel of AMPs and antibiotics in an isogenic Salmonella
enterica sbaA mutant resistant to the porcine AMP PR-39
(Pr€anting et al. 2008). Collectively, these results and ours
support the notion that cross-resistance and immunore-
sistance of AMP-resistant bacteria is context-dependent
(Habets and Brockhurst 2012): it is possible, but not a uni-
versal feature of AMP-resistant clones. Also, in our study,
the in vitro assay was less informative than our in vivo
assay. This highlights the importance of using robust in
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Figure 3 Cross-resistance of pooled selected cultures to antimicrobial
peptides. AMP- and antibiotic-selected Staphylococcus aureus popula-
tions were assessed for resistance to pexiganan, melittin and PGML
using a standard MIC dilution plate assay (n = 3). Intensity of resistance
of a selection line to each stressor is indicated by colour, ranging from
white (MIC = 4 lg mL1) to red (MIC = 64 lg mL1).
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vivo models to parameterize performance of resistant
microbes. Further work is required to determine the
genetic bases of broad-spectrum AMP resistance in these
bacteria.
It was surprising that iseganan-selected bacteria
showed higher survival in vivo but were less pathogenic
than our unselected, streptomycin- and pexiganan-
selected bacteria. Despite this disparity, any antimicrobial
therapy that confers an advantage to infectious bacteria
in vivo is clearly undesirable. One possibility is that the
iseganan-selected bacteria have evolved mutations that
facilitate better survival in the host mediated by reduced
activation of the immune system (Atilano et al. 2011).
An additional possibility is that bacteria at high-density
negatively regulate virulence traits to maximize transmis-
sion (Antia et al. 1994) or that mortality is too crude a
measure of pathology to quantify costs to the host of
infection with AMP-resistant bacteria. Our design, using
mixed populations rather than individual clones, does
not allow us to make causal links between resistance and
pathogenicity of the selected strains because individual
clones within the populations may cause different
phenotypes. It is beyond the scope of the present
manuscript to determine the mechanistic basis of the
reported phenotypes, but future characterization of isog-
enized strains from these populations could be leveraged
to test of the role of AMPs in mediating trade-offs
between resistance and pathogenicity. As subcutaneous
S. aureus must putrefy its host for transmission, such a
trade-off would indicate stabilizing selection on AMP
resistance.
In medical settings, the processes described above may
be exacerbated. AMPs are an important part of the rep-
ertoire of mammalian immune defences (Peschel and
Sahl 2006; Kraus and Peschel 2008; Koprivnjak and
Peschel 2011; Gruenheid and Le Moual 2012). Our find-
ing, that bacteria that have evolved resistance to antimi-
crobial peptides can survive better in vivo, complements
the finding of Habets and Brockhurst (2012) that pexi-
ganan-resistant S. aureus can be cross-resistant in vitro
to the human AMP HNP-1. The feasibility of AMPs as
future antimicrobial therapies is therefore seriously com-
promised: resistant nosocomial infections could pose
serious hazards, particularly for immune-compromised
patients.
In summary, we have shown that an opportunistic path-
ogen can be fitter in a host after selection for antimicrobial
peptide resistance. To our knowledge, this is the first study
linking in vitro antimicrobial peptide resistance to in vivo
survival. The therapeutic use of a single AMP against infec-
tion could ‘arm the enemy’ (Bell and Gouyon 2003) with
cross-resistance to AMPs, including those produced as part
of human immune responses.
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